205 related articles for article (PubMed ID: 17965503)
1. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children.
Nakayama T; Shimada H; Takatsuki S; Hoshida H; Ishikita T; Matsuura H; Saji T
Circ J; 2007 Nov; 71(11):1785-90. PubMed ID: 17965503
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
3. Epoprostenol treatment in children with severe pulmonary hypertension.
Lammers AE; Hislop AA; Flynn Y; Haworth SG
Heart; 2007 Jun; 93(6):739-43. PubMed ID: 17065181
[TBL] [Abstract][Full Text] [Related]
4. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.
Siehr SL; Ivy DD; Miller-Reed K; Ogawa M; Rosenthal DN; Feinstein JA
J Heart Lung Transplant; 2013 May; 32(5):546-52. PubMed ID: 23453572
[TBL] [Abstract][Full Text] [Related]
5. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
7. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension.
Tokunaga N; Ogawa A; Ito H; Matsubara H
J Cardiol; 2016 Dec; 68(6):542-547. PubMed ID: 27005767
[TBL] [Abstract][Full Text] [Related]
8. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
Ogawa A; Miyaji K; Yamadori I; Shinno Y; Miura A; Kusano KF; Ito H; Date H; Matsubara H
Circ J; 2012; 76(7):1729-36. PubMed ID: 22481098
[TBL] [Abstract][Full Text] [Related]
10. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
[TBL] [Abstract][Full Text] [Related]
11. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
Nakayama T; Ishikita T; Matsuura H; Saji T
J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
[TBL] [Abstract][Full Text] [Related]
12. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
[TBL] [Abstract][Full Text] [Related]
14. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
Fisher KA; Serlin DM; Wilson KC; Walter RE; Berman JS; Farber HW
Chest; 2006 Nov; 130(5):1481-8. PubMed ID: 17099027
[TBL] [Abstract][Full Text] [Related]
15. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.
Stiebellehner L; Petkov V; Vonbank K; Funk G; Schenk P; Ziesche R; Block LH
Chest; 2003 Apr; 123(4):1293-5. PubMed ID: 12684325
[TBL] [Abstract][Full Text] [Related]
17. Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center.
Shirai Y; Yasuoka H; Takeuchi T; Satoh T; Kuwana M
Mod Rheumatol; 2013 Nov; 23(6):1211-20. PubMed ID: 23359006
[TBL] [Abstract][Full Text] [Related]
18. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
Kato H; Katori T; Nakamura Y; Kawarasaki H
Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
[TBL] [Abstract][Full Text] [Related]
19. [Feasibility of cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy].
Uchi M; Saji T; Harada T
J Cardiol; 2005 Nov; 46(5):183-93. PubMed ID: 16320975
[TBL] [Abstract][Full Text] [Related]
20. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
